GC Therapeutics uses synthetic biology to program patient-derived stem cells into various cell types in an efficient and scalable manner.
GC Therapeutics has raised $65.0M in total funding. The most recent round was Series A. The last funding was announced in September 2024.
GC Therapeutics's investors include Andreessen Horowitz, Pear VC, Alumni Ventures, Cormorant Asset Management, Global Brain Corporation.
GC Therapeutics is headquartered in Boston, United States.
GC Therapeutics uses synthetic biology to program patient-derived stem cells into various cell types in an efficient and scalable manner.
GC Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"GC Therapeutics — Funding & Investors." VCBacked, September 19, 2024, https://www.vcbacked.co/company/gc-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). GC Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/gc-therapeutics
{{cite web |title=GC Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/gc-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated